Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories has achieved a significant milestone by receiving its first delivery of spider silk fibers from its wholly-owned subsidiary, Prodigy Textiles, based in Vietnam. This marks a critical step in scaling up production to meet growing demand from various sectors, including sports apparel and medical products. The company anticipates fulfilling existing requests, notably from Polartec LLC and MtheMovement. Kraig Labs is transitioning from a developer to a producer of high-quality spider silk, aiming to solidify market partnerships and innovate new products.
Kraig Biocraft Laboratories (OTCQB: KBLB) has filed a patent for its advanced spider silk mass production technologies, particularly focusing on knock-in knock-out gene editing systems for nearly pure spider silk fibers. This application, titled "Modification of Heavy Chain Fibrion in Bombyx Mori," builds on a provisional patent filed in February 2020. CEO Kim Thompson stated that the filing is timely as the company intends to transition this new technology to production soon, emphasizing its core role in commercialization and sales.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has successfully produced and genetically screened a new batch of spider silk silkworm eggs, ready for shipment to Vietnam to resume commercial production. Operations were halted in March due to COVID-19, during which the company enhanced its Dragon Silk strain's performance and genetics. CEO Kim Thompson praised the team's progress, emphasizing that these silkworm eggs signify the future of spider silk production.